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The RNA binding protein DEAD-END (DND1) is one of the few proteins known to regulate microRNA (miRNA)
activity at the level of miRNA-mRNA interaction. DND1 blocks miRNA interaction with the 3′-untranslated region
(3′-UTR) of specific mRNAs and restores protein expression. Previously, we showed that the DNA cytosine deaminase,
APOBEC3 (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide like 3), interacts with DND1. APOBEC3 has
been primarily studied for its role in restricting and inactivating retroviruses and retroelements. In this report, we
examine the significance of DND1-APOBEC3 interaction. We found that while human DND1 inhibits miRNA-mediated
inhibition of P27, human APOBEC3G is able to counteract this repression and restore miRNA activity. APOBEC3G, by
itself, does not affect the 3′-UTR of P27. We found that APOBEC3G also blocks DND1 function to restore miR-372 and
miR-206 inhibition through the 3′-UTRs of LATS2 and CX43, respectively. In corollary experiments, we tested whether
DND1 affects the viral restriction function or mutator activity of APOBEC3. We found that DND1 does not affect
APOBEC3 inhibition of infectivity of exogenous retrovirus HIV (ΔVif) or retrotransposition of MusD. In addition,
examination of Ter/Ter;Apobec3−/− mice, lead us to conclude that DND1 does not regulate the mutator activity of
APOBEC3 in germ cells. In summary, our results show that APOBEC3 is able to modulate DND1 function to regulate
miRNA mediated translational regulation in cells but DND1 does not affect known APOBEC3 function.
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The RNA binding protein DEAD-END (DND1) is essen-
tial for germ cell viability [1,2]. When Dnd1 is function-
ally inactivated, as in the Ter mutant mouse strain, this
results in death of germ cells, sterility [2], and in some
cases development of testicular germ cell tumors [2,3].
DND1 encodes canonical RNA recognition motifs [1,4]
through which it interacts with the 3′-UTRs of mRNAs.
For example, DND1 inhibits miR-221 function from the
3′-UTR of P27 resulting in increased P27 protein expres-
sion [4,5]. Two U-rich DND1 binding sites have been
mapped adjacent to two miR-221 binding sites in the 3′-
UTR of P27 [4]. DND1 has also been shown to inhibit
miR-372 from the 3′-UTRs of LATS2 (serine/threonine-
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reproduction in any medium, provided the orinhibit miR-1 and miR-206 from the 3′-UTRs of CX43
(connexin-43) [4]. However, DND1 binding sites have not
been mapped within the 3′-UTRs of LATS2 or CX43.
miRNA association with mRNA usually results in
translation inhibition or degradation of mRNA. It is
thought that DND1 binds to mRNA and prevents
miRNAs and miRISC (miRNA-induced silencing com-
plexes) from binding. miRISCs are composed of ribonu-
cleoproteins that assemble with the miRNA and mediate
either translational repression or degradation of mRNA
[6-8]. Alternately, DND1 may bind and sequester
mRNAs away from miRNA access.
Although DND1 was initially identified for its role in
germ cells and germ cell tumors, emerging evidence in-
dicates a wider role for DND1 in mammalian tissues, es-
pecially in cancers. For example, over-expression of
DND1 is detected in some histological sub-types of hu-
man testicular cancers, leukemia, lung and ovarian can-
cers (ONCOMINE and NCBI Geo Profiles). A recent
study detected DND1 in human tongue squamous cellThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gets DND1 mRNA [9]. Up-regulation of miR-24 de-
creased DND1 expression resulting in lower P27 levels
and increased proliferation and reduced apoptosis in
TSCC cells. Another study showed that Ras transformed
keratinocytes down regulate DND1 which results in in-
creased miR-21 mediated inhibition of MSH2 [10].
Work in our laboratory and others show that DND1
interacts with a broad range of mRNA targets [11,12].
The targets include transcripts encoding cell cycle regu-
lators (P27, TP53, LATS2), pluripotency factors (OCT4,
SOX2, NANOG) and pro- and anti-apoptotic factors
(BAX and BCLX). Expression of these genes is required
at specific developmental stages in germ cells such as
during active proliferation or quiescence. Because DND1
interacts with a range of mRNAs, this raises the question
as to the factors which might serve to modulate DND1
interaction with physiologically appropriate targets.
Therefore one important goal is to determine how
DND1 function is regulated in cells.
In a related study, we found that DND1 interacts with
APOBEC3 [13]. We showed that mouse DND1 immu-
noprecipitated with mouse APOBEC3 in mammalian
cells, including in germ cells. In addition, fluorescent
tagged DND1 and APOBEC3 co-localized at peri-nuclear
regions in mammalian cells.
One well-studied function of mouse Apobec3 and
its human counterpart, APOBEC3G (apolipoprotein B
mRNA-editing enzyme, catalytic polypeptide-like 3G,
A3G) is contributing to innate immunity through retro-
virus and retrotransposon restriction [14-16]. Restriction
occurs through a well-established cDNA cytosine de-
amination mechanism and by a less well-characterized
deamination-independent mechanism [17-20]. Human
APOBEC3G and mouse APOBEC3, each possess two
zinc-binding motifs [21,22]. The active domain is re-
sponsible for deaminase activity and the pseudo-active
domain contributes most of the RNA/ssDNA binding af-
finity [23-27]. Although both human and mouse proteins
have such a division of labor, the domain organization is
opposite with N-terminal of mouse APOBEC3 and the
C-terminal domain of human APOBEC3G active for de-
amination [28-30].
Other studies indicate that overexpression of specific
members of the human APOBEC3 family (such as the sin-
gle cytidine deaminase domain containing, APOBEC3A)
can hypermutate the cellular genome or mitochondrial
DNA [31,32]. Thus APOBEC3 family members are poten-
tially powerful mutators [33] and very likely cells possess
mechanisms to keep the latent deleterious activity of
APOBEC3 in check. One way that cells protect their
genomes from APOBEC3 is that mouse APOBEC3 and
most human APOBEC3 proteins are localized to the
cytoplasm [14,29,34].In this report, we examined the significance of
APOBEC3 interaction with DND1. Our results show
that APOBEC3 can oppose DND1 function to restore
miRNA-mediated inhibition of translation. We therefore
propose that interaction of APOBEC3 with DND1 may
be one way in which DND1 activity is regulated in cells.
Methods
Transient transfections
Human DND1 with HA tag in C-terminus was cloned
into pCDNA3.1 nV5-DEST (Invitrogen) expression vec-
tor (DND1-HA). Human APOBEC3G with myc tag in
C-terminus was cloned into pcDNA3.1(+)(APOBEC3G-
myc). Transient transfections were performed using the
293 T cell line as this cell line has previously been used
for testing DND1 function [4] and the results using
293 T were similar to that using other cell lines such as
MCF-7 and Tera1. On advantage is that 293 T cells take
up transfected DNA efficiently to give reproducible re-
sults. 293 T cells were cultured in DMEM supplemented
with 10% fetal bovine serum in 5% CO2 at 37°C. The
cells were transiently transfected using SuperFect trans-
fection reagent (QIAGEN) with 1 ng pGL3-P27-3′UTR
[4] together with constructs encoding miRVec-221
(50 ng), DND1-HA (10 ng) and/or APOBEC3G-myc
(1 ng to 25 ng range). LacZ expression constructs (4 ng)
were co-transfected into all cells. Equivalent amounts of
DNA were introduced into all cells with pGEM DNA
being used to equalize for DNA levels used for transfec-
tions. After 48 h the cells were washed and treated with
cell culture lysis buffer (Promega). 5 uL of the lysates
were used for luciferin assays. All transfection experi-
ments were performed in triplicates. Results shown are
the mean and standard error from three independent ex-
periments. Similar transfections also tested the effect of
DND1, APOBEC3G and miR-372 (mirVec-372) on
pGL3 3′UTR LATS2, and miR-206 (miR vec-206) on
pGL3 Cx43 3′UTR and pGL3-control vector. Mutant
P27 vectors used were pGL3 3′UTR min mut1 (m1 or
mut1, in which both DND1 binding sites are mutated)
and pGL3-p27mut-3′-UTR (m3; in which both miRNA
binding sites are mutated) [4].
Statistical analysis
Data are expressed as mean ± standard deviation/or
standard error. Statistical analyses were performed using
GraphPad Prism (software version 5.0. VA). Differences
were determined by Student’s t test. A P value of < 0.05
was considered significant.
Luciferase assays
The assays were performed using Luciferase assay kit
(Pomega) according to manufacturer’s directions. β-
galactosidase assay results were used to normalize the
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done using beta-Glo assay kit (Promega) according to
manufacturer’s direction.
Immunoblotting
DND1-HA and APOBEC3G-myc expression in trans-
fected cells was detected in cell lysates using anti-myc
and anti-HA antibodies, as described [13].
Viral infectivity and MusD transposition assays
Single cycle infectivity assays for HIV(ΔVif) were per-
formed using 293 T cells as described in [28]. MusD
transposition assay in HeLa cells were performed as de-
scribed in [35]. Expression vectors encoding mouse
DND1 and APOBEC3 have been described [13,36].
Mouse crosses
Ter/+ mice were intercrossed with Apobec3−/− mice.
(Both copies of wild-type DND1 are functionally
inactivated in Ter/Ter mice.) The F1 mice were selected
by genotyping and Ter/+;Apobec3+/− mice were inter-
crossed to generate Ter/Ter;Apobec3−/− mice [2,37].
The F2 mice were genotyped and the testes of double
homozygote mice were examined for presence of germ
cells. All mice were housed in the standard mouse Plexi-
glas cages in a room maintained at constant temperature
and humidity under a 12 h light and darkness cycle. Ani-
mals were fed irradiated pelleted chow and water ad
libitum. The experimental protocol was reviewed and
approved by the Institutional Animal Care and Use
Committee at MD Anderson Cancer Center.
Results
APOBEC3 inhibits DND1 function
Kedde et. al. [4] showed that DND1 blocks miR-221
function from the 3′-UTR of P27 mRNA. Also, a report
by Huang et. al. [38] found that human APOBEC3G can
inhibit miRNA function from mRNAs and this indicated
a novel role of APOBEC3G in regulating miRNA activity
and protein translation. Therefore, we asked whether
APOBEC3 affects this function of DND1 and tested the
effect of human APOBEC3G on DND1. Because 3′-
UTR of human P27 has been characterized to contain
two DND1 binding sites flanked by miR-221 binding
sites (Figure 1a) [4], constructs encoding human P27
were predominantly used in these assays, together with
human DND1 and APOBEC3G. We used the reporter
construct, pGL3-P27-3′UTR [4], in which the 3′-UTR
of human P27 has been cloned downstream to luciferase
reporter gene (Figure 1a). pGL3-P27-3′UTR was co-
transfected into 293 T cells together with expression
vectors encoding miR-221, HA-tagged DND1 (HA-tag
in C-terminus of DND1) and myc-tagged APOBEC3G
(myc-tag in C-terminus of APOBEC3G). Luciferase assayswere carried out to monitor the effect of APOBEC3G and
DND1 on miR-221 activity on P27 3′-UTR.
As expected, we found that miR-221 inhibits pGL3-
P27-3′UTR luciferase activity (P = 0.005). DND1 coun-
teracts the effect of miR-221 to restore luciferase activity
(P = 0.01) (Figure 1b). However, when we introduce
APOBEC3G together with DND1, we found that presence
of APOBEC3G opposes DND1 repression of miR-221
(P = 0.009) (Figure 1c). Thus APOBEC3G restores miR-
221 inhibition of pGL3-p27-3′UTR luciferase activity.
APOBEC3G had a similar effect of blocking DND1
function to restore miR-206 inhibition from CX43
(connexin-43; pGL3 Cx43 3′UTR) (P = 0.02) and to re-
store miR-372 inhibition from the 3′-UTR of LATS2
(pGL3 3′UTR LATS2) (P = 0.001) (Figure 1d and 1e). In
these experiments, APOBEC3G restored the miR-
mediated inhibition of luciferase activity but did not fur-
ther increase inhibition. We conclude therefore, that
APOBEC3G may have a general function in blocking
DND1 activity. We verified that transfected plasmids en-
coding HA-tagged DND1 and myc-tagged APOBEC3G
were expressed in the 293 T cells (Figure 1l). We also
detected expression of endogenous DND1, but not
APOBEC3G, in 293 T cells (Figure 1m).
Control experiments demonstrated no significant ef-
fect of either DND1 or APOBEC3G alone (Figure 1f-h) or
DND1 plus APOBEC3G on luciferase activity of pGL3-
P27-3′-UTR, pGL3-Cx43-3′UTR or pGL3-3′UTR-LATS2
(Figure 1i-k).
In further control experiments, we used P27 3′-UTR
constructs in which the DND1 or miRNA binding sites
were mutated [4] (Figure 2b and c). When both DND1
binding sites on pGL3-P27-3′-UTR were inactivated
(m1-luc), miR-221 was able to suppress luciferase activ-
ity but DND1 was unable to rescue miR-221 inhibition
(P = 0.3) and APOBEC3G was not able to restore miR-
221 inhibition (P = 0.3) (Figure 2b). This suggests that
APOBEC3G likely functions, at least partially, through its
interaction with DND1 or through DND1 binding sites on
P27. Use of mutant P27 3′-UTR constructs in which the
miRNA binding sites were mutated (m3-luc) [4] (Figure 2c)
showed, as expected, no functional inhibitory effect of
mir-221 or any further effects by DND1 or APOBEC3G.
Next we tested the effect of higher APOBEC3G con-
centrations on normal and mutant luciferase expression
constructs (Figure 2d-i). Levels that we normally use in
our reporter assays (10 ng), had no effect on pGL3-P27-
3′-UTR, luc-m1, luc-m3 expression (Figure 2d-f ). How-
ever, higher levels of APOBEC3G (25 ng) slightly
inhibited pGL3-P27-3′-UTR (P = 0.023) expression and
on the other hand, slightly enhanced luc-m1 (both
DND1 binding sites mutated) (P = 0.04) and luc-m3 ex-
pression (both miR-221 binding sites mutated) (P = 0.01)
(Figure 2d-f ). We don’t fully understand why higher
Figure 1 APOBEC3G (A3) inhibits DND1 function. (a) Diagram of luciferase construct pGL3-P27-3’-UTR showing miR-221 (blue) and DND1
binding sites (red) [4]. (b) DND1 blocks the effect of miR-221. Luciferase activity of pGL3-P27-3’UTR (or luc-P27 ) alone (lane 1); in the presence of
miR-221 (lane 2); in the presence of DND1 (lane 3); in the presence of miR-221 and DND1 (lane 4). (**) miR-221 inhibited luc-P27 expression
(P = 0.005) and (#) DND1 rescued the inhibition (P = 0.011). LacZ constructs were co-transfected into cells and β-galactosidase used for normalization
of transfection efficiencies. Results are the mean and standard error from 3 independent experiments. (RLU = relative luminescence unit is the ratio
between luciferase and β-galactosidase level, adjusted to 100%). Vectors encoding 1 ng luciferase, 50 ng miR, 10 ng DND1 and 10 ng APOBEC3G were
used in all assays. (c) APOBEC3G counteracts the effect of DND1. Luciferase activity of pGL3-P27-3’UTR in presence of miR-221, DND1 and APOBEC3G
(lane 4). (**) miR-221 inhibited luc-P27 (P= 0.004) (lane 2), (##) DND1 rescued the inhibition (P= 0.008) (lane 3) whereas ($$) APOBEC3G (A3) opposed
the effect of DND1 (P = 0.009) (lane 4). Differences between (**) lane 2 and ($$) 4 are not statistically significant (P=0.0859). (d) pGL3-Cx43-3’UTR
(Luciferase-CX43-3’UTR or luc-CX43) was cotransfected with miR-206, DND1 and APOBEC3G. (*) miR-206 inhibited luc-CX43 (P= 0.017) (lane 2), (#) DND
rescued the inhibition (P= 0.024) (lane 3) whereas ($) A3 opposes DND1(P =0.016) (lane 4). Differences between (*) lane 2 and ($) 4 are not statistically
significant (P= 0.17). (e) pGL3-3’UTR-LATS2 (Luciferase-LATS2-3’UTR or luc-LATS2) was cotransfected with miR-372, DND1 and APOBEC3G. (**) miR-372
inhibited luc-LATS2 (P= 0.001) (lane 2), (##) DND rescued the inhibition (P= 0.001) (lane 3), ($$) whereas A3 opposes DND1 (P = 0.001) (lane 4).
Differences between (**) lane 2 and ($$) 4 are not statistically significant (P=0.176). (f) Control experiments demonstrate no significant effect of DND1
(lane 2) (P = 0.2860) or APOBEC3G alone (lane 3) (P =0.4356) on pGL3-p27-3’UTR; (g) no significant effect of DND1 (lane 2) (P = 0.1426) or APOBEC3G
alone (lane 3) (P = 0.4196) on pGL3-Cx43-3’UTR; (h) no significant effect of DND1 (lane 2) (P = 0.1779) or APOBEC3G alone (lane 3) (P = 0.4615) on
pGL3-3’UTR-LATS2. (i) Control experiments demonstrate no significant effect when DND1 together with APOBEC3G (lane 2) are transfected with pGL3-
p27-3’UTR (P = 0.3433), (j) or pGL3-Cx43-3’UTR (P= 0.3565), (k) or pGL3-3’UTR-LATS2 (P = 0.4183). (l) Expression of HA-tagged DND1 (arrow) and myc-
tagged APOBEC3G (myc-A3) (arrow) in 293T cells (lane 1) and 293T transfected with DND1-HA and APOBEC3G-myc (lane 2). Immunoblotting was
using anti-HA, anti-myc and anti-GAPDH. (m) Expression of endogenous DND1 (arrow) and APOBEC3G (arrow) in 293T cells (lane 1) and 293T
transfected with DND1-HA and APOBEC3G-myc (lane 2). Immunoblotting was using anti-DND1, anti-APOBEC3G and anti-GAPDH antibodies.
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ity. One possibility is that at higher concentrations,
APOBEC3G may have additional functions such as abil-
ity to interact with the 3′-UTRs to inhibit translation
and luciferase activity (of wild-type P27) or promote
translation (from mutant m1 and m3).
Higher APOBEC3G, when present together with miR-
221, also further inhibited pGL3-P27-3′-UTR (or luc-
P27) (P = 0.0488), luc-CX43 (P = 0.0385) and luc-LATS2(P = 0.013) (Figure 2g-i). One explanation for this is
that because 293 T cells express endogenous DND1
(Figure 1m), higher concentrations of APOBEC3G are
able to more effectively block the effect of both en-
dogenous and transfected DND1 to restore miRNA-
mediated inhibition. Also, interestingly, an earlier study
showed that APOBEC3G can, by itself, inhibit miRNA ac-
tivity, and these studies utilized higher, microgram levels
of APOBEC3G [38].
Figure 2 APOBEC3G likely functions through DND1 to restore miRNA activity. (a) APOBEC3G blocks DND1 to restore miR-221 inhibition of
luciferase from wild-type P27-3’-UTR (lane 4). (*) miR-221 inhibited luc-P27 expression (P = 0.0116) (lane 2), (#) DND1 rescued the inhibition (P= 0.0138)
(lane 3). ($) APOBEC3G opposed the function of DND (P = 0.0467) (lane 4). (b) APOBEC3G does not restore miR-221 inhibition from mutated P27 3’-UTR
in m1 (or luc-m1; in which both DND1 binding sites mutated) [4] (lane 4). (*) miR-221 inhibited luc-m1 expression (P= 0.0460). DND1 does not rescue
miR-221inhibition (P=0.2665) (lane 3) and A3 does not affect DND1 function (P = 0.3211). (c) miR-221 does not inhibit m3 (or luc-m3, both miRNA
binding sites mutated [4]) (P= 0.2665) (lane 2). DND1 (P= 0.1184) (lane 3) or A3 (P= 0.4569) (lane 4) also do not affect luc-m3 activity. (d) Effect of
increasing levels of APOBEC3G on wild-type pGL3-P27-3’-UTR. APOBEC3G was cotransfected at two concentrations (10 ng and 25 ng). Higher
APOBEC3G (A3) (25 ng) inhibits (*) pGL3-P27-3’-UTR (lane 3) (P=0.023). (e) Higher A3 (25 ng) slightly enhances luc-m1 expression (*) (lane 3) (both
DND1 binding sites mutated) (P=0.0432). (f) Higher A3 (25 ng) also enhances luc-m3 expression (*) (lane 3) (both miR-221 binding sites mutated)
(P = 0.0141). However, lower A3 levels (10 ng) have no effect on pGL3-P27-3’-UTR, luc-m1, luc-m3 expression (lane 2 in d, e and f: P= 0.0798, 0.3567
and 0.4544 respectively). (g) Effect of increasing APOBEC3G on miR function. miR-221 inhibits luc-P27 (P = 0.0153) (lane 2). A3 (10 ng), together with
miR-221, does not further inhibit luc-P27 (P = 0.4553). However, A3 at 25 ng (lane 4), together with miR-221, further inhibits luc-P27 (P= 0.0488). (h) miR-
206 inhibits luc-CX43 (P=0.0105) (lane 2). A3 (10 ng), together with miR-221 does not further inhibit luc-CX43 (P = 0.4765). However, 25 ng A3 (*)
(lane 4), together with miR-221, further inhibits luc-CX43 (P= 0.0385). (i) miR-372 inhibits luc-LATS2 (P= 0.0011) (lane 2). A3 (10 ng), together with miR-
221 does not further inhibit luc-LATS2 (P= 0.1673). However, 25 ng A3 (*) (lane 4), together with miR-221, further inhibits luc-LATS2 (P = 0.013).
(j) Increasing levels of APOBEC3G have no effect on luciferase translation. Control luciferase reporter, pGL3-luciferase (1 ng) was cotranfected with
increasing concentrations (10 ng and 25 ng) of APOBEC3G expression constructs (P= 0.4021 and P = 0.4573 respectively).
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pGL3-control vector. Increasing levels of APOBEC3G
did not affect the luciferase activity from pGL3-control
vector implying that APOBEC3G did not affect trans-
lation of luciferase (Figure 2j). The pGL3 vector does
not have an extensive 3′-UTR with miRNA or DND1
binding sites unlike the 3′-UTRs of P27, CX43 or
LATS2, and therefore is not affected by higher levels
of APOBEC3G.
In summary, these experiments lead us to conclude that
APOBEC3G is able to block DND1 function and restore
miRNA-mediated translation repression. APOBEC3G
does not directly affect the 3′-UTRs of P27, CX43 or
LATS2 or miRNA interaction with mRNAs. However,
higher levels of APOBEC3G appear to have additional in-
dependent functions on the 3′-UTRs of genes.DND1 does not affect APOBEC3 function
The above results show that APOBEC3G can block
DND1 function to regulate miRNA activity. However,
mouse APOBEC3 and human APOBEC3G have been
widely studied for their role in inhibiting viral infectivity
[14-16]. Therefore, we tested whether DND1 affects
APOBEC3 function of inhibiting retroviral infectivity
[28,39]. Single cycle infectivity assay shows that, as
expected, mouse APOBEC3 severely reduces HIV(ΔVif )
viral infectivity in 293 T cells (Figure 3a, lane 3). How-
ever, presence of mouse DND1 together with APOBEC3
did not change ability of APOBEC3 to reduce HIV(ΔVif)
infectivity (Figure 3a, lane 4). DND1 alone also had no
effect on HIV(ΔVif ) viral infectivity (Figure 3a, lane 2).
Empty vector was used to equalize the amount of con-
struct used in each assay lane [28,39].
Figure 3 DND1 does not affect APOBEC3 function. (a) DND1 does not affect APOBEC3 antiretroviral activity. Infectivity of HIV-GFP produced
in the presence of control vector (vector) (lane 1) or vector encoding mouse DND1 (lane 2) (P = 0.2082). Infectivity of HIV-GFP produced in the
presence of mouse APOBEC3 (A3) (lane 3) and APOBEC3 plus DND1 (lane 4) (P = 0.1464). Empty vector was used to equalize the amount of
construct used in each assay lane. Results from two independent experiments were averaged. Error bars indicate the difference in infectivity
observed between the two experiments. (b) DND1 does not affect MusD restriction by APOBEC3. Effect of control vector (lane 1), mouse DND1
(lane 2), mouse APOBEC3 (lane 3), both mouse DND1 and APOBEC3 (lane 4) on MusD retrotransposition, relative to the vector control. Transposition
was monitored by the number of G418-resistant colonies. Results from two independent experiments were averaged. P value comparing lanes 3 and 4
is 0.10980. (c) Histology section through testes of double homozygous male Ter/Ter ;A3−/− (or Ter/Ter; Apobec3−/−), (d) Ter/Ter and (e) wild-type (+/+)
mice. Arrow points to lumen in seminiferous tubules showing lack of germ cells persist in Ter/Ter ; A3−/− testis similar to that in testis of Ter/Ter mice.
Testes of Apobec3−/− (A3−/−) mice have normal wild-type germ cell histology similar to +/+ (not shown). (f) Proposed model how APOBEC3G
regulates DND1 function. DND1 blocks miRNA activity (left panel). We observe decreased protein translation (as measured by luciferase activity) in the
presence of APOBECG3 suggesting that APOBEC3G blocks DND1 function. When DND1 binding sites on P27-3′-UTR are inactivated, both DND1 and
APOBEC3G fail to affect luciferase activity. This suggests that APOBEC3G functions through DND1, may be by removing or sequestering DND1 to
restore miRNA access to the 3′-UTR of P27 (right panel).
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DND1 affects the ability of APOBEC3 to inhibit MusD
retrotransposition [35]. APOBEC3, by itself, drastically
inhibits MusD retrotransposition (as indicated by decrease
in neoR colonies by Apo3 + vector) (Figure 3b, lane 3).
However, DND1, when combined with APOBEC3, did not
significantly affect APOBEC3 function of inhibiting MusD
retrotransposition (A3 +DND1, lane 4). DND1, by itself,
also had no effect on MusD retrotransposition (vector +
DND1, lane 2). The results from these two experiments
indicate that DND1 does not modulate the viral restriction
function of APOBEC3.
To further explore the functional relationship between
Dnd1 and Apobec3, we asked whether the germ cell
phenotype of mice lacking wild-type Dnd1 (Ter mutant
mice) is dependent on Apobec3. It is known that
APOBEC3 family members are potentially powerful
mutators [31-33]. We reasoned that interaction of
DND1 with APOBEC3 in germ cells may be one mech-
anism to keep the latent deleterious activity ofAPOBEC3 in check. Thus it is formally possible that de-
pletion of germ cells in mice lacking normal Dnd1 (as
observed in Ter mutant mice) is due to uncontrolled
Apobec3 genomic mutating activity. We therefore tested
whether removing Apobec3 from mice in which Dnd1 is
inactivated, would restore normal germ cells. Mice lack-
ing wild-type Dnd1 (in Ter mice) have no germ cells [2]
but mice lacking Apobec3 are normal and fertile [37].
Thus, we generated double mutant mice lacking both
wild-type Dnd1 and Apobec3 (Ter/Ter;Apobec3−/− or
Ter/Ter;A3−/−) mice. However, examination of newborn
or adult testes of Ter/Ter;A3−/− mice indicated that they
have no germ cells and are sterile (Figure 3c) and are in-
distinguishable from Ter/Ter;A3+/+ animals (Figure 3d).
Thus this genetic assay suggests that DND1 does not
regulate the mutator function of APOBEC3 in germ cells
and germ cell loss.
in Ter/Ter mice is likely not due to unregulated activ-
ity of APOBEC3. Together, results from the restriction
assays and the genetic crosses are consistent with the
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activity.
Discussion
Our results demonstrate that APOBEC3G is able to
block DND1 function and restore miRNA mediated in-
hibition of translational repression. This function of
APOBEC3G appears to apply to multiple mRNA targets
of DND1 as APOBEC3G has a similar effect on P27,
LATS2 and CX43. On the other hand, DND1 does not
appear to affect the viral restriction function of
APOBEC3. In addition, our genetic crosses suggest that
DND1 interaction with APOBEC3 does not regulate the
mutator function of APOBEC3 in germ cells.
The mechanism of how APOBEC3G blocks DND1 re-
mains to be determined. At least, three possible mecha-
nisms can be proposed. The first possibility is that
APOBEC3G may bind to DND1 and sequester it away
from mRNAs and miRNAs (Figure 3f ). In support of
this, we have observed that mouse APOBEC3 and DND1
co-immunoprecipitate and co-localize in cells [13].
The second possibility is that APOBEC3G may bind
mRNAs (maybe together with DND1) and subsequently
interact with components of the miRISC to activate
translation repression or interact with translation initi-
ation factors to inhibit them. Indeed, mass spectrometric
analysis show that a large number of cellular RNA-
binding proteins associate with APOBEC3G [40-42].
Some of these are known components of the miRISC
such as ARGONAUTE 1(Ago1), ARGONAUTE 2
(Ago2), GW182, MOV10, YB-1, DCP1A and RCK/P54,
and are involved in post-transcriptional silencing of gene
expression [38,41-43]. These interactions of APOBEC3G
with RNA binding proteins were found to be either dir-
ect protein-protein interactions or mediated by RNA. In
addition, confocal microscopy experiments showed that
APOBEC3G co-localized with many of the miRISC
RNA-binding proteins to mRNA processing, P-bodies
[40,41]. Thus it is conceivable that interaction of
APOBEC3 with specific miRISC proteins may override
the effect of DND1 to enhance miRNA activity.
The third possibility is that the cytidine deaminase ac-
tivity of APOBEC3 may allow it to edit the 3′-UTR se-
quences of P27, LATS2 and CX43 to inhibit DND1
binding. Interestingly, indirect support of this hypothesis
comes from recent reports by a number of groups that
analysed deep sequencing data and found greater than
expected incidence of editing present in the mammalian
transcriptome [44,45]. As to which of the three possible
mechanisms apply to APOBEC3G blocking DND1 func-
tion is currently under investigation.
APOBEC3 proteins have been studied as factors that
restrict viruses and retrotransposons. However, we found
that DND1 has no effect on the viral restriction functionof APOBEC3. APOBEC3G can bind both cellular RNAs
and RNA binding proteins [27,40,41] and the RNA bind-
ing activity of the N-terminal cytidine deaminase domain
of APOBEC3G is essential for viral restriction [23,24].
The significance of APOBEC3G interactions with cellu-
lar proteins and RNAs is not clear. However, during viral
infection of cells, such as HIV-1 (Vif ) infection of T
lymphocytes, APOBEC3G gains access to viral particles
through a ribonucleoprotein interaction and thus
APOBEC3 binding to RNA is a critical for antiviral func-
tion [23]. The incorporation of APOBEC3G into new
viral particles allows it to be released into infected cells
where APOBEC3G can deaminate the replicating viral
cDNAs to effect reduction of viral infectivity. Interest-
ingly, it has been shown that other P-body proteins, such
as MOV10 [46-48] are also involved in reducing the in-
fectivity of exogenous retroviruses and retrotransposons.
Thus, P-body protein components such as MOV10, and
as we report here, APOBEC3G, participate both in
miRNA silencing and viral restriction processes.
An earlier study on APOBEC3G function showed that
APOBEC3G can, by itself, inhibit miRNA activity [38].
The previous study used luciferase constructs encoding
only miRNA binding sites or encoding multiple miRNA
binding sites in tandem. In contrast, our assays used the
3′-UTR of endogenous genes to test APOBEC3G activ-
ity and we also tested how APOBEC3G blocks DND1
function on these 3′-UTRs. Moreover, the amount of
APOBEC3G expression vectors transfected into cells
were considerably higher in the study [38] and we also
found that higher APOBEC3G levels may have alternate
effects on the 3′-UTRs and miRNA function. Another
possibility is that APOBEC3G may have different effects
on different miRNAs and transcripts, inhibiting some
miRNAs while activating others.
One caveat of our studies is that the miRNA studies
were performed using human DND1 and APOBEC3G
whereas the infectivity assays and genetic studies were
performed using mouse factors. We did this because
human DND1 function was previously characterized
using human P27 3′-UTR and DND1 binding sites have
been mapped in the 3′UTR of P27 [4]. Humans encode
multiple members of the APOBEC3 family proteins
(APOBEC3A, 3B, 3C, etc.) [21]. We selected human
APOBEC3G for our miRNA studies which is function-
ally most closely related to mouse APOBEC3. The role
of the other human APOBEC3 factors in inhibiting
DND1 activity remains to be determined.
APOBEC3 proteins are expressed in germ cells
[13,21,49]. But although APOBEC3 proteins inhibit
retrotransposition [17,50,51], to date, this has not been
demonstrated in germ cells. In fact, Apobec3 null mice
are normal and fertile [37]. We found that double null
Ter/Ter;Apobec3−/− mice have similar phenotype as
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Ter/Ter (Dnd1−/−) phenotype to restore germ cells. This
supports the idea that DND1 does not regulate the muta-
tor activity of APOBEC3 in germ cells, and deregulated
APOBEC3 mutator activity is not responsible for germ cell
loss in Ter/Ter (Dnd1−/−) mice.
In summary, our studies focus on a novel aspect of
APOBEC3 function in that we show APOBEC3G regu-
lates DND1 function and in this way affects miRNA ac-
tivity. Viral restriction and miRNA mediated gene
silencing are evolutionarily related processes utilizing
similar protein complexes, which localizes to cytoplas-
mic RNA granules. Our data provides compelling evi-
dence that APOBEC3G may be involved in both these
processes.
Conclusion
We present our novel finding that RNA binding protein
DEAD END (DND1) blocks miRNA function to permit
translation, and APOBEC3G (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide like 3) antagonizes
DND1 to reduce translation. Not much is known about
how microRNA target interactions are regulated by
RNA binding proteins, thus our result advances an area
of importance to help understand how microRNA activ-
ity can be modulated in response to signals.
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